We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rhizen

News List

Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or refractory marginal zone lymphoma, follicular lymphoma expresspharma
February 09, 2021
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics at an IND stage (TGR 1202) in 2012.
Rhizen Pharma, Curon Biopharma sign exclusive licensing pact to develop and commercialise Tenalisib in Greater China expresspharma
October 15, 2020
Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $149.5 million-plus double-digit royalties on annual net sales of Tenalisib.
Rhizen receives US FDA orphan drug designation expressbpd
December 27, 2017
The US Food and Drug Administration (US FDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing.